The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | MRD-guided treatment with sonrotoclax plus obinutuzumab in treatment-naive CLL: BGB-11417-101
Marc Hoffman, MD, University of Kansas Medical Center, Kansas City, KS, shares initial results from the Phase I/Ib BGB-11417-101 study (NCT04277637) of sonrotoclax plus obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia (CLL). Dr Hoffman highlights that the study used measurable residual disease (MRD) status to guide treatment discontinuation, with follow-up ongoing to assess progression-free survival rates. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
